Page last updated: 2024-12-06

o-demethylencainide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

O-demethylencainide: encainide metabolite with longer half-life; identified in plasma of patient receiving encainide orally; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54736
SCHEMBL ID11265684
MeSH IDM0104271

Synonyms (26)

Synonym
4-hydroxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide
mj-9444
encainide, o-demethyl-
benzamide, 4-hydroxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-
o-demethylencainide
mj 9444
o-desmethyl-encainide
brn 0497009
(+-)-4-hydroxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide
benzamide, 4-hydroxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-, (+-)-
4-hydroxy-n-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide
37612-09-2
o-desmethylencainide
81329-70-6
unii-xqu4s7n0ah
xqu4s7n0ah ,
QMHJFCPHRGVEAF-UHFFFAOYSA-N
4-hydroxy-2'-[2-(1-methyl-2-piperidyl)ethyl]-benzanilide
4-hydroxy-2'-[2-(1-methyl-2-piperidyl)ethyl]benzanilide
SCHEMBL11265684
o-desmethyl encainide
4-hydroxy-2'-(2-(1-methyl-2-piperidyl)ethyl)benzanilide
4-hydroxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide, (+/-)-
4-hydroxy-n-(2-(2-(1-methylpiperidin-2-yl)ethyl)phenyl)benzamide
4-hydroxy-n-{2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl}benzamide
DTXSID70958660

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of drugs that undergo extensive presystemic hepatic metabolism may be increased by concomitant ingestion with food."( Impact of food on the bioavailability of encainide.
Destache, CJ; Hilleman, DE; Malesker, MA; Mohiuddin, SM; Nipper, HC; Stoysich, AM, 1992
)
0.28

Dosage Studied

ExcerptRelevanceReference
" Twenty-four-hour ambulatory ECGs were obtained at baseline for each daily dosage of 75 mg, 150 mg, and 225 mg of encainide during the in-hospital titration period and at the end of the first and sixth months during the follow-up period."( Long-term efficacy and safety of oral encainide in the treatment of chronic ventricular ectopic activity: relationship to plasma concentrations--a French multicenter trial.
Barnay, C; Cheymol, G; Coumel, P; Dumoulin, P; Flammang, D; Jaillon, P; Kher, A; Medvedowsky, JL; Poirier, JM; Valty, J, 1985
)
0.27
" Three-times-a-day dosing was as effective as 4-times-a-day dosing."( Dosing recommendations for encainide.
Antonaccio, MJ; Verjee, S, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (73.08)18.7374
1990's7 (26.92)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.80 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (13.79%)5.53%
Reviews3 (10.34%)6.00%
Case Studies1 (3.45%)4.05%
Observational0 (0.00%)0.25%
Other21 (72.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]